Comparison of immune responses of mice immunized with five different mycobacterium bovis BCG vaccine strains

Infection and Immunity

Volumn 64, Issue 1, 1996, Pages 1-9

  Lagranderie, Micheline R R ^a   Balazuc, Anne Marie ^a   Deriaud, Edith ^a   Leclerc, Claude D ^a   Gheorghiu, Marina ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BCG VACCINATION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG FORMULATION; LYMPHOCYTE PROLIFERATION; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BCG VACCINE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; IMMUNITY, CELLULAR; IMMUNOGLOBULIN ISOTYPES; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MYCOBACTERIUM BOVIS; PEYER'S PATCHES; SPECIES SPECIFICITY; SPLEEN; T-LYMPHOCYTES; TUBERCULIN; TUBERCULOSIS; VACCINATION; VACCINES, SYNTHETIC;

EID: 0030026839     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.1.1-9.1996     Document Type: Article

References (40)

1. Abou-Zeid, C., G. A. Rook, D. E. Minninkin, J. H. Parlett, T. W. Osborn, and J. M. Grange. 1987. Effect of the method of preparation of Bacille Calmette-Guérin (BCG) vaccine on the properties of four daughter strains. J. Appl. Bacteriol. 63:449-453.
2. Abou-Zeid, C., I. Smith, J. Grange, J. Steele, and G. Rook, 1986. Subdivision of daughter strains of Bacille Calmette-Guérin (BCG) according to secreted protein patterns J. Gen. Microbiol. 132:3047-3053.
3. Bloom, B. R., and P. E. Fine. 1994. The BCG experience: implications for future vaccines against tuberculosis, p. 521-557. In B R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, D.C.
4. Calmette, A., C. Guérin, L. Nègre, and A. Boquet. 1926. Prémunition des nouveaux-nés contre la tuberculose par le vaccin BCG, 1921-1926. Ann Inst. Pasteur (Paris) 40:89-133
5. Chan, J., and S. H. E. Kaufmann. 1994. Immune mechanisms of protection, p 389-415. In B. R Bloom (ed) Tuberculosis, pathogenesis, protection and control. American Society for Microbiology, Washington, D.C.
6. Clemens, J. D., J. H. Jackie, J. H. Chuong, and A. R. Feinstein. 1983. The BCG controversy, methodological and statistical reappraisal. JAMA 249: 2362-2369
7. Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdik, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis Meta-analysis of the published literature JAMA 271:698-702.
8. Collins, F. M. 1994. The immune response to mycobacterial infection: development of new vaccines. Vet. Microbiol. 797:1-16.
9. Comstock, G. W. 1994. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol. Rev. 16:77-89
10. Dubos, R. J., and C. H. Pierce. 1956. Differential characteristics in vitro and in vivo of several substrains of BCG. Am. Rev Tuberc. Pulm. Dis 74: 655-717
11. - T-cell help. J Immunol. 147:4069-4073.
12. Fomukong, N. G., J. W. Dale, T. W. Osborn, and J. M. Grange. 1992. Use of gene probes based on the insertion sequence IS 986 to differentiate between BCG vaccine strains. J. Appl Bacteriol 72:126-133
13. Frappier, A., V. Portelance, J. St.-Pierre, and M. Panisset. 1971 BCG strains: characteristics and relative efficacy. Status of immunization in tuberculosis in 1971 Department of Health, Education, and Welfare publication 72. Fogarty International Center Proceedings no 14 National Institutes of Health, Bethesda, MD. 68:157-178.
14. Gheorghiu, M. Unpublished data.
15. Gheorghiu, M., J. Augier, and P. H. Lagrange. 1983 Maintenance and control of the French BCG strain 1173-P2 (primary and secondary seed-lots). Bull. Inst. Pasteur 81:281-288.
16. Gheorghiu, M., M. R. R. Lagranderie, B. M. E. Gicquel, and C. D. Leclerc. 1994. Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect. Immun. 62:4287-4295
17. Gheorghiu, M., and P. H. Lagrange. 1983. Viability, heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains. Ann. Inst. Pasteur Immunol. 134C:125-147.
18. Gheorghiu, M., P. H. Lagrange, and C. Fillastre. 1988. The stability and immunogenicity of a dispersed grown freeze-dried Pasteur BCG vaccine. J. Biol Stand. 16:15-26.
19. 18a. Gicquel, B. Unpublished data.
20. - T lymphocytes in intracellular microbial infections. Immunol. Today 9:168-174
21. Kaufmann, S. H. E. 1993. Immunity to intracellular bacteria, p. 1251-1286. In W. E. Paul (ed.). Fundamental immunology, 3rd ed Raven Press, New York.
22. Lagranderie, M., A. Murray, B. Gicquel, C. Leclerc, and M. Gheorghiu. 1993. Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. Vaccine 11:1283-1290.
23. Mackaness, G. B., and R. V. Blanden. 1967. Cellular immunity. Prog Allergy 11:89-140
24. Minnikin, D. E., S. M. Minnikin, G. Dobson, M. Goodfellow, F. Portaels, L. Van den Breen, and D. Sesardic. 1983 Mycolic acid patterns of four vaccine strains of Mycobacterium bovis BCG. J. Gen. Microbiol. 129:889-891.
25. Munk, M. E., J. De Bruyn, H. Gras, and S. H. E. Kaufmann. 1994. The Mycobacterium bovis 32-kilodalton protein antigen induces human cytotoxic T-cell responses. Infect. Immun. 62:726-728.
26. Murray, A., N. Winter, M. Lagranderie, D. F. Hill, J. Rauzier, J. Timm, C. Leclerc, K. M. Moriarty, M. Gheorghiu, and B. Gicquel. 1992. Expression of Escherichia coli β-galactosidase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses. Mol Microbiol 6:3331-3342
27. Organisation Mondiale de la Santé. 1980. Les politiques de vaccination par le BCG. Série de Rapports Techniques no. 652. Organisation Mondiale de la Santé, Geneva.
28. Orme, I. M. 1993. Immunity to mycobacteria Curr. Opin. Immunol. 5: 497-502.
29. Osborn, T. W. 1983 Changes in BCG strains. Tubercle 64:1-13.
30. Rook, G. A. W., J. Steele, M. Ainsworth, and B. R. Champion. 1986 Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology 59:333-338.
31. Sekhuis, V. M., H. Freudenstein, and J. L. Sirks. 1977. Report on results of a collaborative assay of BCG vaccines organized by International Association of Biological Standardization J. Biol Stand 5:85-109
32. Skamene, E. 1986. Genetic control of resistance to mycobacterial infection Curr. Top. Microbiol Immunol. 124:49-66.
33. Smith, D., G. Harding, J. Chan, M. Edwards, J. Hank, D. Muller, and F. Sobhi. 1979. Potency of 10 BCG vaccines as evaluated by their influence on the bacillemic phase of experimental airborne tuberculosis in guinea-pias J. Biol Stand. 7:179-197.
34. Stover, C. K., G. P. Bansal, M. S. Hanson, J. E. Burlein, S. R. Palaszynski, J. F. Young, S. Koenig, D. B. Young, A. Sadziene, and A. G. Barbour. 1993. Protective immunity elicited by recombinant bacille Calmette-Guérin (BCG) expressing outer surface protein A (osp A) lipoprotein. a candidate Lyme disease vaccine. J Exp Med. 178:197-209.
35. Stover, C. K., V. F. de la Cruz, T. R. Fuerst, J. E. Burbeiny, L. A. Benson, L. T. Benett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull, S. B. Snapper, R. G. Barletta, J. Jacobs, and B. R. Bloom. 1991. New use of BCG for recombinant vaccines. Nature (London) 351:456-460
36. Ten Dam, H. G. 1993 BCG vaccination, p. 251-269. Marcel Dekker, Inc., New York.
37. Winter, N., M. Lagranderie, S. Gangloff, C. Leclerc, M. Gheorghiu, and B. Gicquel. 1995. Recombinant BCG strains expressing the SIV mac 251 nef gene induce proliferate and CTL responses against nef synthetic peptides in mice Vaccine 13:471-478.
38. Winter, N., M. Lagranderie, J. Rauzier, J. Timm, C. Leclerc, B. Guy, M. P. Kieny, M. Gheorghiu, and B. Gicquel. 1991. Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene 109:47-54
39. World Health Organization. 1979. Tuberculosis prevention trials: Madras. Trial of BCG vaccines in South India for tuberculosis prevention Bull. W.H.O. 57:819-827
40. World Health Organization. 1979. Hxpert Committee on Biological Standardization. Requirements for dried BCG vaccine. WHO Tech. Rep. Ser. 638:116-147.